Search results for: 'cell ad gene therapy cold chain'

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule the...

23 Oct 2020  |  Global  |  Market Research

Supply Chain Optimization and Decentralized Manufacturing to Expand the Contract Cell and Gene Therapy Manufacturing Market, 2020–2026

Automation Deployed to Contain Cost of Goods Sold and Vector Manufacturing Standardization will Create New Growth Opportunities

Infographics

×

The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space. While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind. To fully harness the curative potential of these therapies and ensure greater reach and a...

24 Oct 2018  |  North America  |  Market Research

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market

Infographics

×

Key Issues Addressed

The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

This study explores the global immuno-oncology (I-O) markets evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions. The study considers oncology agents for which the immune syst...

Recent advancement in the development of novel platforms of smart targeting small molecules, gene therapy, stem cell therapy, gene modification, and gene rectification technologies pose new prospects for therapies and cures for rare and genetic diseases. More than 80% of rare diseases are genetic in origin, so that gene and cell therapies are being...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...